Bioxcel therapeutics announces journal of the american medical association publication of data from serenity ii pivotal phase 3 trial evaluating bxcl501 in bipolar disorders

Bxcl501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo

BTAI Ratings Summary

BTAI Quant Ranking